We are live on ! Find out more
TAK icon

Takeda Pharmaceutical
TAK

315 hedge funds and large institutions have $1.2B invested in Takeda Pharmaceutical in 2025 Q2 according to their latest regulatory filings, with 50 funds opening new positions, 134 increasing their positions, 66 reducing their positions, and 33 closing their positions.

New
Increased
Maintained
Reduced
Closed

12,219% more call options, than puts

Call options by funds: $26.6M | Put options by funds: $216K

103% more repeat investments, than reductions

Existing positions increased: 134 | Existing positions reduced: 66

52% more first-time investments, than exits

New positions opened: 50 | Existing positions closed: 33

14% more capital invested

Capital invested by funds: $1.06B → $1.2B (+$146M)

3% more funds holding

Funds holding: 307 → 315 (+8)

2.02% less ownership

Funds ownership: 4.47% → 2.45% (-2%)

Holders
315
Holders Change
+8
Holders Change %
+2.61%
% of All Funds
4.15%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
50
Increased
134
Reduced
66
Closed
33
Calls
$26.6M
Puts
$216K
Net Calls
+$26.4M
Net Calls Change
+$1.11M

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$42M
2
UBS Group
UBS Group
Switzerland
+$33.5M
3
Morgan Stanley
Morgan Stanley
New York
+$28.3M
4
BlackRock
BlackRock
New York
+$13.6M
5
Bank of America
Bank of America
North Carolina
+$10.6M

Top Sellers

Rank Fund Capital Flow
1
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$13.3M
2
VanEck Associates
VanEck Associates
New York
-$12.4M
3
Goldman Sachs
Goldman Sachs
New York
-$12.1M
4
Toronto Dominion Bank
Toronto Dominion Bank
Ontario, Canada
-$9.63M
5
Verition Fund Management
Verition Fund Management
Connecticut
-$6.54M
Name Holding Trade Value Shares
Change 		Change in
Stake
Capital Research Global Investors
1
Capital Research Global Investors
California
$206M +$1.4M +94,569 +0.7%
Morgan Stanley
2
Morgan Stanley
New York
$118M +$28.3M +1,917,066 +34%
Goldman Sachs
3
Goldman Sachs
New York
$69.6M -$12.1M -819,828 -15%
Fidelity Investments
4
Fidelity Investments
Massachusetts
$63.4M +$3.5M +236,563 +6%
UBS Group
5
UBS Group
Switzerland
$62.2M +$33.5M +2,270,084 +129%
BIP
6
Brandes Investment Partners
California
$57.4M +$3.08M +208,136 +6%
BlackRock
7
BlackRock
New York
$54.9M +$13.6M +920,044 +35%
Renaissance Technologies
8
Renaissance Technologies
New York
$51M +$2.09M +141,500 +4%
Millennium Management
9
Millennium Management
New York
$47.8M +$42M +2,842,012 +1,152%
First Trust Advisors
10
First Trust Advisors
Illinois
$40.2M -$2.28M -154,147 -6%
Adage Capital Partners
11
Adage Capital Partners
Massachusetts
$39.2M -$13.3M -899,298 -26%
Northern Trust
12
Northern Trust
Illinois
$31.4M +$5.76M +389,972 +24%
MAP
13
Managed Asset Portfolios
Michigan
$23M +$283K +19,177 +1%
VanEck Associates
14
VanEck Associates
New York
$20.6M -$12.4M -840,952 -39%
Arrowstreet Capital
15
Arrowstreet Capital
Massachusetts
$18.8M -$2.69M -181,766 -13%
Bank of America
16
Bank of America
North Carolina
$16M +$10.6M +718,805 +226%
Wells Fargo
17
Wells Fargo
California
$15.7M +$668K +45,195 +5%
Envestnet Asset Management
18
Envestnet Asset Management
Illinois
$13.6M -$167K -11,309 -1%
QCM
19
Quantinno Capital Management
New York
$12.3M +$4.15M +280,992 +54%
CGH
20
Crossmark Global Holdings
Texas
$11.2M +$4.88M +330,361 +83%
Federated Hermes
21
Federated Hermes
Pennsylvania
$8.26M -$117K -7,892 -1%
Royal Bank of Canada
22
Royal Bank of Canada
Ontario, Canada
$7.19M +$352K +23,797 +5%
Stifel Financial
23
Stifel Financial
Missouri
$7.02M +$772K +52,237 +13%
Natixis Advisors
24
Natixis Advisors
Massachusetts
$7.01M +$491K +33,249 +8%
QCM
25
QRG Capital Management
Illinois
$6.69M +$676K +45,726 +12%
1
2 3 4 5

TAK Hedge Fund Activity: Q2 2025 in Review

315 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Takeda Pharmaceutical (TAK) for Q2 2025, worth a combined $1.2B — up 14% from $1.06B a quarter earlier.

Buyers outnumbered sellers: 50 funds opened new TAK positions and 33 closed out — a net gain of 17 holders — while 134 added to existing stakes and 66 trimmed.

The largest buyer was Millennium Management, adding an estimated $42M. The largest seller was Adage Capital Partners, cutting an estimated $13.3M.

  • 315 institutional investors held Takeda Pharmaceutical (TAK) as of Q2 2025, up from 307 in Q1 2025.
  • Funds reported $1.2B of Takeda Pharmaceutical stock for Q2 2025, up 14% quarter-over-quarter.
  • 50 funds opened new Takeda Pharmaceutical positions in Q2 2025 and 33 closed out, a net change of +17 holders.
  • The largest Takeda Pharmaceutical buyer in Q2 2025 was Millennium Management, an estimated $42M added.
  • The largest Takeda Pharmaceutical seller in Q2 2025 was Adage Capital Partners, an estimated $13.3M sold.

Based on aggregated 13F filings for Q2 2025.